which was acquired by Optum in 2021. Landmark provided in-home primary care to seniors in value-based care arrangements with payors. Through Johnson's vision, Bluebird Kids Health aims to combine ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma ...

Non-alcoholic drinks play a major role in Asahi’s corporate vision. As part of its Legacy 2030 strategy ... The company says the unit has a proprietary ‘BlueBird’ cooling innovation that helps to ...

So, from 1997 to 2021 at least, you can find E450s equipped ... as long as it gets proper maintenance. In any case, the Blue Bird Vision is also the only vehicle not manufactured by Ford to ...

Flying high as one of the world’s premier developers of gene therapies in early 2018, bluebird bio’s share ... In August of 2021, the company pulled up its stakes in Europe, with Obenshain ...

Prior to founding Bluebird, Johnson served as CEO of Landmark Health, a value-based operator of in-home primary care for seniors. The company was acquired by Optum in 2021. Bluebird Kids Health ...

Leschly served as Bluebird’s CEO or “chief Bluebird” from 2010, when the company changed its name from Genetix Pharmaceuticals, to 2021, when he oversaw Bluebird’s 2021 spin-out of its ...

Bluebird has struggled financially in the last few years, with high development costs and slower-than-expected market adoption limiting revenue growth. In 2021, the company withdrew from the ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global ...

When tech founders build products, they can’t always know what those tools will eventually become or how people will use them. That sentiment is echoed repeatedly by early Twitter employees in a new ...

bluebird bio (NASDAQ:BLUE) lost ~37% in the premarket on Friday after the gene therapy developer announced its plans to become a privately held biotech as part of an M&A agreement with private ...